- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00543569
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Loma Linda, California, Stany Zjednoczone, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90033
- University of Southern California - University Hospital
-
Los Angeles, California, Stany Zjednoczone, 90057
- St. Vincent/National Institute of Transplantation
-
Sacramento, California, Stany Zjednoczone, 95817
- UC Davis Medical Center
-
San Diego, California, Stany Zjednoczone, 92103
- UCSD
-
San Diego, California, Stany Zjednoczone, 92123
- California Institute of Renal Research/Sharp Memorial Hospital
-
San Francisco, California, Stany Zjednoczone, 94143
- University of California - San Francisco
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Health Science Center
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone, 32610
- University of Florida, Shands Hospital, Gainesville
-
Jacksonville, Florida, Stany Zjednoczone, 32224
- Mayo Clinic - Jacksonville
-
-
Georgia
-
Augusta, Georgia, Stany Zjednoczone, 30921
- Medical College of Georgia, Augusta
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois at Chicago
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University Of Chicago Medical Center
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rush - Presbyterian - St. Lukes Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- University of Maryland Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan
-
-
New Jersey
-
Livingston, New Jersey, Stany Zjednoczone, 07039
- St. Barnabas Medical Center
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14203
- Buffalo General Hospital
-
New York, New York, Stany Zjednoczone, 10029
- Mt. Sinai School of Medicine
-
New York, New York, Stany Zjednoczone, 10065
- New York Presbyterian Hospital - Cornell
-
Valhalla, New York, Stany Zjednoczone, 10595
- Westchester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- University of North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health & Science University
-
Portland, Oregon, Stany Zjednoczone, 97210
- Legacy Transplant Services
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Stany Zjednoczone, 17101
- Pinnacle Health at Harrisburg
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- University of Pennsylvania
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38104
- Methodist University Hospital - Memphis
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75246
- Baylor University Medical Center
-
Houston, Texas, Stany Zjednoczone, 77030
- Methodist Hospital Research Institute of Houston
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84132
- University of Utah Medical Center
-
-
Virginia
-
Richmond, Virginia, Stany Zjednoczone, 23298
- Virginia Commonwealth University School of Medicine
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98195
- University of Washington Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure
- Subject is a recipient of a de novo kidney transplant
- Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical related living donor, a non-related living donor, or a deceased donor
Exclusion Criteria:
- Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+ T-cell count of < 250 cells/µL
- Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30 hours
- Recipient has a positive T or B-cell cross match by investigational site's standard method of determination
Subject will receive a kidney from a 50-65 year old deceased donor with one of the following:
- History of hypertension and a terminal serum creatinine > 1.5 mg/dL
- Cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL
- History of hypertension and cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Tacrolimus/MMF/Basiliximab
Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
|
The initial dose of tacrolimus was administered orally within 48 hours post-transplant.
Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Inne nazwy:
Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
Inne nazwy:
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Inne nazwy:
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
|
|
Eksperymentalny: Alefacept QW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
|
The initial dose of tacrolimus was administered orally within 48 hours post-transplant.
Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Inne nazwy:
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Inne nazwy:
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Inne nazwy:
|
|
Eksperymentalny: Alefacept QW/Tacrolimus
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
|
The initial dose of tacrolimus was administered orally within 48 hours post-transplant.
Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Inne nazwy:
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Inne nazwy:
|
|
Eksperymentalny: Alefacept QOW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
|
The initial dose of tacrolimus was administered orally within 48 hours post-transplant.
Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Inne nazwy:
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Inne nazwy:
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review
Ramy czasowe: 6 months
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR. The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit. |
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Patient Survival at Month 6 and Month 12
Ramy czasowe: 6 months and 12 months
|
Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
6 months and 12 months
|
|
Graft Survival at Month 6 and Month 12
Ramy czasowe: 6 months and 12 months
|
Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
6 months and 12 months
|
|
Percentage of Participants With BCAR at Month 12 Assessed by Local Review
Ramy czasowe: 12 months
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR. The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
12 months
|
|
Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review
Ramy czasowe: 6 months and 12 months
|
Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
6 months and 12 months
|
|
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review
Ramy czasowe: 6 months and 12 months
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
6 months and 12 months
|
|
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review
Ramy czasowe: 6 months and 12 months
|
Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit. |
6 months and 12 months
|
|
Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12
Ramy czasowe: Week 4, Month 6 and Month 12
|
The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.
|
Week 4, Month 6 and Month 12
|
|
Change From Week 4 in GFR by Iothalamate Clearance at Month 6
Ramy czasowe: Week 4 and Month 6
|
The glomerular filtration rate was measured directly using iothalamate clearance.
|
Week 4 and Month 6
|
|
Change From Week 4 in Serum Creatinine at Month 6 and 12
Ramy czasowe: Week 4 and Month 6 and 12
|
Week 4 and Month 6 and 12
|
|
|
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review
Ramy czasowe: 6 months and 12 months
|
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to local review, or lost to follow-up.
|
6 months and 12 months
|
|
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review
Ramy czasowe: 6 months and 12 months
|
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to central review, or lost to follow-up.
|
6 months and 12 months
|
|
Time to First BCAR Assessed by Local Review
Ramy czasowe: 12 months
|
The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.
Only participants with a BCAR are included in the analysis.
|
12 months
|
|
Time to First BCAR Assessed by Central Review
Ramy czasowe: 12 months
|
The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1.
Only participants with a BCAR are included in the analysis.
|
12 months
|
|
Time to First T-cell Mediated BCAR Assessed by Local Review
Ramy czasowe: 12 months
|
The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.
|
12 months
|
|
Time to First T-cell Mediated BCAR Assessed by Central Review
Ramy czasowe: 12 months
|
The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1.
Only participants with a T-cell mediated BCAR are included in the analysis.
|
12 months
|
|
Maximum Grade of T-cell Mediated Rejection Assessed by Local Review
Ramy czasowe: 6 months and 12 months
|
The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis. Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation. |
6 months and 12 months
|
|
Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review
Ramy czasowe: 6 months and 12 months
|
The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis. Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation. |
6 months and 12 months
|
|
Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12
Ramy czasowe: 6 months and 12 months
|
Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.
|
6 months and 12 months
|
|
Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12
Ramy czasowe: 6 months and 12 months
|
Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol. The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event. |
6 months and 12 months
|
|
Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12
Ramy czasowe: 6 months and 12 months
|
All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.
|
6 months and 12 months
|
|
Percentage of Participants With Treatment Failure at Month 6 and 12
Ramy czasowe: 6 months and 12 months
|
Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively.
Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.
|
6 months and 12 months
|
|
Gastrointestinal Quality of Life Index Score Over Time
Ramy czasowe: Months 1, 3, 6, and 12
|
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score.
The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never).
Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.
|
Months 1, 3, 6, and 12
|
|
Gastrointestinal Symptom Rating Scale Scores Over Time
Ramy czasowe: Months 1, 3, 6, and 12
|
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS).
The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort).
Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.
|
Months 1, 3, 6, and 12
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Principal Investigator, University of Michigan
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki dermatologiczne
- Środki przeciwbakteryjne
- Antybiotyki, Przeciwnowotworowe
- Środki przeciwgruźlicze
- Antybiotyki, Przeciwgruźlicze
- Inhibitory kalcyneuryny
- Takrolimus
- Kwas mykofenolowy
- Bazyliksymab
- Alefacept
Inne numery identyfikacyjne badania
- 0485-CL-U201
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .